SGRYHealthcare · Medical Care FacilitiesThe 12 Wall Street analysts covering Surgery Partners, Inc. hold a median 12-month price target of $19 — +30.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Surgery Partners, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (68): Sales and profits are climbing, and climbing faster than before.
Momentum (32): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SGRY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +30.9% from it.
Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $18 |
| 11 Aug 2026 | RBC Capital | Maintains | Outperform | $20 → $19 |
| 11 Aug 2026 | TD Cowen | Maintains | Buy | $17 → $19 |
| 5 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 5 Mar 2026 | Mizuho | Maintains | Outperform | $19 → $17 |
| 5 Mar 2026 | TD Cowen | Maintains | Buy | $28 → $20 |
| 5 Mar 2026 | TD Cowen | Maintains | Buy | — |
| 5 Mar 2026 | UBS | Maintains | Buy | — |
| 5 Mar 2026 | UBS | Maintains | Buy | $29 → $21 |
| 4 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 4 Mar 2026 | RBC Capital | Maintains | Outperform | $31 → $20 |
| 3 Mar 2026 | Barclays | Maintains | Equal-Weight | $18 → $14 |
| 3 Mar 2026 | Barclays | Maintains | Equal-Weight | — |
| 18 Dec 2025 | Mizuho | Maintains | Outperform | — |
| 24 Nov 2025 | JP Morgan | Maintains | Neutral | — |
| 21 Nov 2025 | Barclays | Maintains | Equal-Weight | — |
| 17 Nov 2025 | Mizuho | Maintains | Outperform | — |
| 13 Nov 2025 | UBS | Maintains | Buy | — |
| 11 Nov 2025 | Benchmark | Maintains | Buy | — |
| 11 Nov 2025 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGRY appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 81% of US stocks
Cheaper than 71% of US stocks
Cheaper than 33% of US stocks
Higher than 33% of US stocks
Higher than 41% of US stocks
Higher than 21% of US stocks
Higher than 70% of US stocks
Higher than 27% of US stocks
Higher than 48% of US stocks
Higher than 69% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Surgery Partners, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reported that weak July jobs data has raised hopes for Federal Reserve easing, putting health care and select retail ETFs and stocks in focus.
Why it matters — As a health-care company, Surgery Partners could be among the stocks viewed favorably in a potential Fed easing environment.
Seeking Alpha published the transcript of Surgery Partners, Inc.'s (SGRY) second-quarter 2026 earnings call. The item provides the full text of management's discussion during the earnings call.
Why it matters — SGRY watchers would refer to this transcript for management's own commentary on the company's second-quarter results and outlook.
Surgery Partners reported second-quarter 2026 revenue and adjusted EBITDA that came in above its internal expectations and reaffirmed its full-year outlook. This comes ahead of the anticipated sale of its Idaho Falls market operations to Intermountain Health.
Why it matters — A SGRY watcher would care because the company beat its own internal targets for the quarter and maintained its full-year guidance as it moves forward with the planned divestiture of its Idaho Falls operations.
Surgery Partners (SGRY) reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, though down from $0.17 per share in the same quarter last year.
Why it matters — The earnings beat suggests the company performed better than analysts expected in the quarter, offering a current snapshot of financial performance relative to consensus forecasts.
Surgery Partners (SGRY) shares rose 5.3% in the last session on above-average trading volume. The article notes that recent earnings estimate revisions may not lead to further price increases in the near term.
Why it matters — SGRY watchers would care because the stock saw a significant price surge on high volume, though the cautious outlook on earnings revisions suggests limited near-term upside.
The 12 Wall Street analysts covering Surgery Partners, Inc. have a median 12-month price target of $19, with estimates ranging from $14 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Surgery Partners, Inc., 9 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Surgery Partners, Inc. 47 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Surgery Partners, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (68 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +30.9% from the last close, and Ticker Nerd's factor model ranks Surgery Partners, Inc. 47 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Surgery Partners, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $24 over the next 12 months.
Surgery Partners, Inc. returned -36.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Surgery Partners Inc. is a healthcare services holding company that owns and operates a national network of surgical facilities and ancillary services across more than 200 locations in 33 states.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Likely ETF & Stock Winners From July Jobs Report". Zacks Investment Research reported that weak July jobs data has raised hopes for Federal Reserve easing, putting health care and select retail ETFs and stocks in focus.
Surgery Partners Inc. is a healthcare services holding company that owns and operates a national network of surgical facilities and ancillary services across more than 200 locations in 33 states. It specializes in short-stay surgical care, managing ambulatory surgery centers and surgical hospitals that provide non-emergency procedures in specialties such as orthopedics, pain management, ophthalmology, gastroenterology, and general surgery. The company supports these operations through integrated ancillary services, including multi-specialty physician practices, anesthesia services, diagnostic laboratories, urgent care facilities, and optical services like laboratories and group purchasing organizations. Surgery Partners Inc. focuses on delivering high-quality, cost-effective outpatient care, differentiating itself with a comprehensive model that enhances patient and physician support in the ambulatory healthcare sector. Founded in 2004 and headquartered in Brentwood, Tennessee, it plays a key role in the U.S. healthcare delivery system by emphasizing efficient surgical solutions.
CEO Mr. J. Eric Evans · 16,000 employees · United States · https://www.surgerypartners.com